What can be done for patients with cancer of the digestive tract in 2003? Guidelines of the francophone federation of digestive tract concerology - Part I;Que faire devant un cancer digestif en 2003? Recommandations de la fédération francophone de cancérologie digestive (FFCD) première partie

Gastroenterologie Clinique et Biologique

Volumn 26, Issue 12, 2002, Pages 1140-1164

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ANUS CANCER; CANCER CLASSIFICATION; CANCER THERAPY; CARDIA CARCINOMA; COLON CANCER; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; INTESTINE CARCINOMA; METASTASIS; PRACTICE GUIDELINE; RECTUM CANCER; REVIEW; STOMACH CANCER;

EID: 1442277171     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-8.
2. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281:1623-7.
3. Bedenne L, Michel P, Bouche O, Triboulet JP, Conroy T, Pezet D, Roullet B, Seitz JF, Lacourt J, Milan C. Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alon (FFCD 9102). Proc Am Soc Clin Oncol 2002:519.
4. Bumm R, Wong J. Extent of lymphadenectomy in esophagectomy for squamous cell carcinoma: what is necessary? Dis Esophagus 1994;7:151-6.
5. Siewert JR, Stein HJ. Carcinoma of the cardia: carcinoma of the gastroesophageal junction-classification, pathology and extent of resection. Dis Esophagus 1996:9:173-82.
6. Jacob JH, Seitz JF, Langlois C, Raoul JL, Bardet E. Bouché O, et al. Definitive concurrent chemoradiation therapy in squamous cell oesophageal cancer. Results of a french randomized trial comparing standard versus split-course irradiation (FNCLCC - FFCD 9305). Proc Am Soc Clin Oncol 1999;18:270a.
7. Minsky BD, Pajack TF, Ginsberg R, Pisansky T, Martenson J, Komaki R, Okawa G, Rosenthal SA, Kelsen DK 1. INT0123 phase III trial of combined modality therapy for eosophageal cancer: high dose versus standard-doseradiation therapy. J Clin Oncol 2002,20;5:1167-1174.
8. Walsh TN, Nooman N, Holywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7.
9. Bosset JF. Gignoux M, Triboulet JP. Tiret E, Mantion G, Elias D, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-7.
10. Medical Research Council Oesophageal Cancer Working party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33.
11. Sibille A, Lambert R, Souquet JC, Sabben G, Descos F. Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology 1995;108:337-44.
12. Ell C, May A, Gossner L, Pech O, Gunter E, Mayer G, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000;118:670-7.
13. Maingon P, d'Hombres A, Truc G, Barillot I, Michiels C, Bedenne L, et al. High dose rate brachytherapy for superficial cancer of the esophagus. Int J Radiat Oncol Biol Phys 2000;46(1):71-6.
14. Roussel A, Chèze S, Jacob JH, Ollivier JM, Macé-Lesec'h J, Henry-Amar M. Radiation therapy in esophageal carcinoma with broncho-tracheal involvement: The centre François Baclesse Experience. Proc Am Soc Clin Oncol 1995;14:438a.
15. Siewert JR, Stein HJ. Carcinoma of the cardia: carcinoma of the gastroesophageal junction-classification, pathology and extent of resection. Dis Esophagus. 1996:9:173-82.
16. Rougier Ph, Ducreux M, Mahjoubi M, Pignon JP, Belleqih S, Oliveira J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994;30A:1263-9.
17. Bonenkamp, Hermans J, Sasako M, van de Velde CHJ and the Dutch gastric cancer group. Extended lymph node dissection for gastric cancer. N Engl J Med 1999;340:908-14.
18. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347:995-9.
19. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;34:725-30.
20. Murad A, Santiago F, Petroianu A, Rocha P, Rodrigues M, Raush M. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993;72:97-41.
21. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
22. Glimelius B, Ekstrom K. Randomised comparison between chemotherapy plus best supportive care with plus best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
23. Van de Velde CJH. Lymph node dissection in gastric cancer: 5-year results of a randomized trial of D1 and D2 dissection in 996 Dutch patients (abstract). Proc Am Soc Clin Oncol 1996;16:278a.
24. Cuschieri A, Weeden S, Fielding J, Bancewitz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the Medical research council (MRC) randomised surgical trial. Br J Cancer 1999;79:1522-30.
25. Bunt AM, Hermans J, Boon MC, et al. Evaluation of the extent of lymphadenectomy in a randomized trial of westem-versus Japanese-type surgery in gastric cancer. J Clin Oncol 1994;12:417-22.
26. Elias D. Surgical technique of extended lymph node excision (type R2 and R3) in gastric adenocarcinomas. Ann Chir 1995;49:13-23.
27. Elias D. Reflections and proposals for the worldwide standardization of lymphadenectomy for gastric carcinoma. J Surg Onc 1999;71:120-2.
28. 1 lymph node metastases. Br J Surg 1996;83:1144-1147.
29. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
30. Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, et al. New developments in the treatment of gastric carcinoma. Semin Oncol 1990;17(suppl 2):61-70.
31. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin a step ahead in the treatment of advanced gastric cancer; a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;5:827-31.
32. Wilke H, Wils J, Rougier Ph, Lacave A, Van Cutsem E, Vanhoefer U, et al. Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer. A trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group and the AIO (abstract). Proc Am Soc Clin Oncol 1995;14:206a.
33. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA. Krook JE, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 1994;12:412-6.
34. Kim NK, Park YS, Heo DS, Suh C, Kim SY. Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-8.
35. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E. J Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Clin Oncol 2000;18:3874-5.
36. Mitry E, Artru P, Taïeb J, Boige V, Vaillant JN, Clavero-Fabri MC, et al. Chimiothérapie des cancers avancés de l'œsophage, du cardia et de l'estomac par l'association LV5FU2+CDDP. Gastroenterol Clin Biol 2000;24:A177.
37. Lecomte Th, Mitry E, Taieb j, Boige V, Desrame J, Vaillant JM, et al. Chimiothérapie des cancers de l'estomac et du pancréas métastatique: comparaison non randomisée de 2 schéma d'association 5 FU - CDDP (FUP et LV5FU2 - P). Gastroenterol Clin Biol 2001;25: A105.
38. , Pozzo C, Bugat R, Peschel C, et al. Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC): final results of a randomised phase II study (abstract). Proc Am Soc Clin Oncol 2001;20:328a.
39. Lecomte T, Louvet C, André T, Ychou M, Gamelin E, Mousseau M, et al. L'association docetaxel-épirubicine en 2ème ligne de chimiothérapie pour des patients atteints d'un cancer gastrique avancé: résultats préliminaires d'une étude de phase II (abstract). Gastroenterol Clin Biol 2000;24:178a.
40. Seymour MT, Dent JT, Papamichael D, Cresswell HE, Wilson G. Epirubicin (E) cisplatin (C) and oral UFT (U): an active and convenient regimen in upper gastrointestinal cancer (abstract). Proc Am Soc Clin Oncol 1998;17:259a.
41. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0,4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
42. Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999;17:2901-8.
43. Tournigand C. Louvet C, Quinaux E, Andre T, Lledo G, Flesch M, et al. Folfiri followed by Folfox versus Folfox followed by Folfiri in metastatic colorectal cancer (MRC): final results of a phases III study. Proc Am Soc Clin Oncol 2001;19:abst 494.
44. Ross P. Norman A, Cunningham D, Webb A, Iveson T, Padhani A, et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997;8:995-1001.
45. Seitz JF, Perrier H, Giovannini M, Bernadini D, Capodano G, Girodengo L, et al. 5-Fluorouracil, highdose Folinic Acid an Mitomycine C combination chemotherapy in preciously treated patients with advanced colorectal carcinomas. J of Chem 1998;10: 258-65.
46. Gilly FN, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994;41:124-9.
47. Elias D, Gachot B, Bonvallot S, Blot F, Sabourin JC, Ducreux M, et al. Peritoneal carcinosis treated by complete excision and immediate postoperative intra-peritoneal chemotherapy. Phase II study in 54 patients. Gastroenterol Clin Biol 1997;21:181-7.
48. Ducreux M, Dominguez S, Chouraki N, Bexon A, Fabri MC, Zimmermann P, et al. La linite gastrique atteint des malades jeunes et répond peu à la chimiothérapie (abstract). Gastroenterol Clin Biol 1998;22:159a.
49. Neugut AI, Marvin MR, Rella VA, Chabot JA. An overview of adenocarcinoma of the small intestine. Oncology (Huntingt) 1997; 11:529-36.
50. Locher C, Boige V, Kergoat P, Prougier Ph, Elias D, Lasser P, et al. Résultats de l'association 5-Fluorouracile (5FU)/sel de platine dans les adénocarcinomes du grêle localement avancés et/ou métastatiques. Gastroenterolo Clin Biol 2001;25:A182.
51. Patt YZ, Hoque A, Jones D, Markowitz A. Phase II trial of cisplatinum, 5FU and leucovorin (PFL) for primary duodenal carcinoma (PDC). Proc Am Soc Clin Oncol 1995;14:221(abstr).
52. Conférence de Consensus. Conclusions et recommandations du jury. Texte de Consensus. Prévention, dépistage et prise en charge des cancers du côlon. Gastroenterol Clin Biol 1998;22:S275-88.
53. Erlichman C, Marsoni S, Seitz JF, Skillings J, Shepard L, Zee B, et al. Event free and overall survival is increased by FUFA in resected B colon cancer: a pooled analysis of five randomized trials (RCTS) International multicentre pooled analysis of B2 colon cancers trials (IMPACT B2) investigators. J Clin Oncol 1999;17:1356-63.
54. Zaniboni A, Labianca R, Marsoni S, Torri V, Mosconi P, Grilli R, et al. GIVIO-SITAC 01: a randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma Long term results and evaluation of the indicators of health-related quality of life. Cancer 1998;82:2135-44.
55. IMPACT investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
56. Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994;106:899-906.
57. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246-50.
58. Moertel CG, Fleming TR, Mac Donald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
59. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (5FU) leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc Am Soc Clin Oncol 1998;17:256a.
60. Andre T, Colin P, Louvet C. Gamelin E, Bouche O, Achille E, et al. Phase III trial (GERCOR C96.1) comparing bimonthly LV5FU2 to monthly 5FU-leucovorin high dose (LV HD) in patients with Dukes B2 and C colon cancer. Proc Am Soc Clin Oncol 2002:529.
61. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-15.
62. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. Cancer 1996;77:1254-62.
63. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938-46.
64. Portier G, Milan C, Elias D, Gillet M, Bosset JF, Bouché O, et al. Etude randomisée multicentrique de phase III: chimiothérapie systémique adjuvante contre observation après résection de métastases hépatiques d'origine colo-rectale. Essai FFCD-ACHBTH-AURC 9002. Gastroenterol Clin Biol 2002;26:A70.
65. Elias D. Métastases hépatiques synchrones et résécables d'origine colo-rectale: faut-il les réséquer d'emblée ou secondairement? Hepato-Gastro 1996;3:177-80.
66. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. J Clin Oncol 1989;7:1437-46.
67. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993;306:752-5.
68. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The nordic gastrointestinal tumor adjuvant therapy group. Cancer 1994;73:556-62.
69. Beretta G, Bollina R, Cozzi C, Beretta GA, Morbito A. Should we consider the weekly (w), chemotherapy (CT) with fluorouracil (F) + racemic folinic acid (f) a standard treatment for advanced/metastatic carcinoma of digestive tract (DTC) in elderly patients (pts)? (abstract). Proc Am Soc Clin Oncol 1997;16:259a.
70. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992;10:904-11.
71. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of non resectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-20.
72. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
73. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Navarro M, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12.
74. Rougier P, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. Br J Surg 1995;82:1397-400.
75. Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-17.
76. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a french intergroup study. J Clin Oncol 1997;15:808-15.
77. Tournigand C, de Gramont A, Louvet C, André T, Carola E, Gilles Amar V, et al. A simplified bimonthly regiment with leucovorin (LV) and 5-fluorouracil (5FU) for metastatic colorectal cancer (MCRC) (abstract). Proc Am Soc Clin Oncol 1998;17:274a.
78. Scheithauer W, Kornek G, Marczell A, Salem G, Karner J, Kovats E, et al. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure I-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. J Clin Oncol 1997;15:908-14.
79. Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, et al. Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Tomudex colorectal cancer study group. Ann Oncol 1996;7:961-5.
80. Cocconi G, Cunningham D, Van Cutsem E, François E, Gustavsson B, van Hazel G, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex colorectal cancer study group. J Clin Oncol 1998;16:2943-52.
81. Pazdur R, Vincent M. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (SFU + LV) in patients with advanced colorectal cancer (ACC) results of a randomized multicenter North American trial (abstract). Proc Am Soc Clin Oncol 1997;16:228a.
82. Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002;359:1537-8.
83. Seitz JF, Bennouna J, Paillot B, Gamelin E, Francois E, Conroy T, et al. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Ann Oncol 2002;13:1072-9.
84. Giacchetti S, Zidani R, Perpoint B, Pinel MC, Faggiuolo R, Focan C. et al. Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC) (abstract). Proc Am Soc Clin Oncol 1997;16:229a.
85. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and 5-fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 2000;18:2938-47.
86. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-47.
87. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14.
88. Twelves C, Harper P, Van Cutsem E, Thibault A, Shelygin YA, Burger HU, et al. A phase III trial (SO14796) of Xeloda (Capecitabine) in previously untreated advanced/metastatic colorectal cancer. [Abstract] Proc Am Soc Clin Oncol 1999;18:263a.
89. Cox JV, Pazdur R, Thibault A, Maroun J, Weaver C, Jahn MW, et al. A phase III trial of XELODA ™ (Capecitabine) in previously untreated advanced metastatic colorectal cancer. [Abstract] Proc Am Soc Clin Oncol 1999;18:265a.
90. Pazdur R, Douillard JY, Skillings JR, Eisenberg PD, Davidson N, Harper P, et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. [Abstract] Proc Am Soc Clin Oncol 1999;18:263a.
91. Carmichael J, Popiela T, Radstone S, Falk S, Fey M, Oza A, et al. Randomized comparative study of ORZEL (oral uracil/tegafur (UFT) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. [Abstract] Proc Am Soc Clin Oncol 1999;18:264a.
92. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252-8.
93. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-8.
94. Levi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovolin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994;86:1608-17.
95. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 1997;350:681-6.
96. Gamelin E, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, et al. Relationship between 5-fluorouracil (5FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5FU. Cancer 1996;77:441-51.
97. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998;16:1470-8.
98. Elias D, Ducreux M, Lasser P, Boige V, Blot F, Rougier P, El Otmany A, Antoun S. Carcinoses péritonéales (CP) d'origine colorectale traitées dans une optique curatrice par résection complète et chimiothérapie intrapéritonéale (CIP). Résultats: 64 cas. Gastroenterol Clin Biol 2001;25:A72.
99. Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999;17:2901-8.
100. Tournigand C, Louvet C, Quinaux E, Andre T, Lledo G, Flesch M, et al. Folfiri followed by Folfox versus Folfox followed by Folfiri in metastatic colorectal cancer (MRC): final results of a phases III study. Proc Am Soc Clin Oncol 2001;19:abst 494.
101. Izzo J, Cvitkovic E, Zarba J, Rougier Ph, Villalobos W, Ducreux M, et al. Low dose 5FU continuous infusion (FUCL) in advanced colorectal cancer (ACC): clinical evidence for reversal of acquired intrinsic resistance to 5FU or 5FU folinic (FU-FO) (abstract). Ann Oncol 1992;3:20a.
102. Ducreux M, Rougier Ph, Voni-Hanitrimanga R, Elias D, Fabri MC, Zimmermann P, et al. Chimiothérapie de deuxième ligne des métastases de cancers colorectaux par perfusions continues de 5-fluorouracile (5FU) modulées par l'acide folinique (AF) ou le méthotrexate (MTX). Essai de phase I-II avec étude pharmacocinétique.(abstract) Gastroenterol Clin Biol 1996;20:35a.
103. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997;8:995-1001.
104. Chester JD, Dent JT, Wilson G, Ride E, Seymour MT. Protracted infusional 5-fluorouracil (5FU) with bolus mitomycin C in 5-FU-resistant colorectal cancer. Ann Oncol 2000;11:235-7.
105. Ducreux M, Coquard R. Traitement adjuvant du cancer du rectum. Gastroenterol Clin Biol 1996;20:858-72.
106. De Calan L, Mosnier H, Gouillat C. Cancer du rectum: bilan et traitement chirurgical curatif. Gastroenterol Clin Biol 1996;20:645-56.
107. Abel ME, Rosen L, Kodner IJ, Fleshman JW, Hicks T, Kennedy HL, et al. Practice parameters for the treatment of rectal carcinoma. Dis Colon Rectum 1993;36:989-1006.
108. Heald RJ. Total mesorectal excision is optimal surgery for rectal cancer: a scandinavian consensus. Br J Surg 1995;82:1297-9.
109. Heald RJ, Moran BJ, Ryll RD, Sexton R, Mac Farlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998;133:894-9.
110. Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000;356:93-6.
111. Fischer B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham L, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988;80:21-9.
112. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980-7.
113. Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: A metaanalysis. JAMA 2000;284:1008-15.
114. Kapiteijne E, Marijnen CAM, Nagtegaal I, Putter H, Steup W, et al. for the Dutch colo-rectal cancer group. Preoperative radiotherapy combined with total mesorectal excision for respectable rectal cancer. N Engl J Med 2001;345:638-46.
115. Marijnen CAM, Kapiteijne E, Van de Velde CJU, Martijn H, Steup W, et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomised trial. J Clin Oncol 2002;20:817-25.
116. Pahlman L, Glimelius B. Pre or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg 1990;211:187-95.
117. Gerard A, Buyse M, Nordlinger B, Loygue J, Pene F, Kempf P, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208:606-14.
118. Stockholm Rectal Cancer Study Group. Preoperative short-term radiation therapy in operable rectal carcinoma. Cancer 1990;66:49-55.
119. Frykholm GJ, Isacsson U, Nygard K, Montelius A, Jung B, Pahlman L, et al. Preoperative radiotherapy in rectal carcinoma. Aspects of acute adverse effects and radiation technique. Int J Radiat Oncol Biol Phys 1996;35:1039-48.
120. Swedish Rectal Cancer Trial. Initial report from a swedish multicentre study examining the role of preoperative irradiation in the treatment of patients with resectable rectal carcinoma. Br J Surg 1993;80:1333-6.
121. Grann A, Minsky BD, Cohen AM, Saltz L, Guillem JG, Paty PB, et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum 1997;40;5:515-22.
122. Hyams DM, Mamounas EP, Petrelli N, Rickette Hn, Jones J, Wieand HS, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum 1997;40:131-9.
123. Lasser P. Débats actuels sur le cancer du rectum. Gastroenterol Clin Biol 2002;26:B78-88.
124. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465-72.
125. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
126. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonalds JS, Haller DG, et al. Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-7.
127. Tepper JE, O'Connell MJ, Petroni GR, Hollis D, Cooke E, Benson AB, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 1997;15:2030-9.
128. Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000;92:388-96.
129. Lasser P, Toma C, Pompili P, Ducreux M, Fabri MC, Elias D, et al. Cancer du rectum et métastases synchrones non résécables: intérêt d'une association radiothérapie (RT) + chimiothérapie (CT) + chirurgie (résumé). Gastroenterol Clin Biol 1995;19:53A.
130. UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996; 348:1049-1054.
131. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and a salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527-39.
132. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the european organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 1997;15:2040-9.
133. Peiffert D, Seitz JF, Rougier P Francois E, Cvitkovic F, Mirabel X, Nasca S, Ducreux, M, Hannoun-Levi JM, Lusinchi A, Debrigode E, Conroy T, Pignon JP, Gerard JP. Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. Ann Oncol 1997;8:575-81.
134. Papillon J, Montbarbon JF. Epidermoid carcinoma of the anal canal. A series of 276 cases. Dis Colon Rectum 1987;30:324-33.